Orodispersible and Innovative Dosage Forms: Advances in Preparation Technologies, Direct Compression, and Co-Processed Excipients
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: closed (25 July 2025) | Viewed by 2400
Special Issue Editors
Interests: orodispersible tablets; minitablets; pediatric formulations; parenteral nutrition
Interests: pharmaceutical technology; biopharmaceutics; artificial intelligence; machine learning; data science
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Although orodispersible tablets (ODTs) were introduced to the pharmaceutical market more than 25 years ago, this dosage form still remains a subject of interest for many pharmaceutical technologists as well as innovators from pharma companies. ODTs are gaining more and more popularity in the pharmacotherapy of many diseases, including both acute and chronic kinds.
Initially produced via freeze-drying, ODT manufacturing now predominantly utilizes direct compression or post-granulation tableting. This shift is largely attributed to the development of superdisintegrants and the advent of co-processed excipients exhibiting superior compression properties. These advancements significantly reduce disintegration time and enhance the mechanical properties of compressed ODTs, streamlining production.
Current trends highlight the emergence of third-generation ODTs, incorporating modified-release formulations such as microcapsules, coated micropellets, and sustained-release granules. These formulations greatly simplify administration for pediatric patients and individuals with swallowing difficulties. Furthermore, the development of orodispersible minitablets (ODMTs and MODTs) and the exploration of alternative manufacturing technologies like 3D printing represent significant areas of ongoing research.
This Special Issue welcomes review articles and original research encompassing all aspects of fast-dissolving oral dosage forms. We welcome submissions covering a broad spectrum of topics, from the conceptualization and formulation of innovative orodispersible systems—including orodispersible films, granules, and buccal films—to their pharmacokinetic profiles and clinical trial data. This issue also welcomes studies on chewable tablets, buccal dosage forms, mucoadhesive dosage forms, and the broader application of co-processed excipients in improving the tabletability of various tablet formulations, including modified-release tablets. The enhanced tabletability afforded by co-processed excipients is especially relevant for direct compression methods. We encourage submissions exploring all aspects of these advanced dosage forms and their impact on patient care.
Dr. Witold Brniak
Prof. Dr. Aleksander Mendyk
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- orodispersible films
- buccal films
- chewable tablets
- orodispersible granules
- buccal dosage forms
- mucoadhesive dosage forms
- tabletability
- modified release tablets
- minitablets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
